Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics, Inc. reported a Q2 2026 net loss of $42.7 million, improved from $50.9 million a year earlier, on collaboration revenue of $4.6 million from terminating its Overland Therapeutics license. Operating expenses fell to $51.6 million from $56.8 million, driven mainly by lower research and development spending.
Cash, cash equivalents and investments totaled $423.6 million as of June 30, 2026, supported by a $187.9 million April 2026 public equity offering and $20.7 million raised via at-the-market sales. The company expects this liquidity to fund operations into the first quarter of 2029, while still acknowledging the need for additional capital to fully execute its plans.
Allogene continues to focus on three core programs: the pivotal ALPHA3 trial of cema‑cel in first‑line large B‑cell lymphoma, the TRAVERSE Phase 1b trial of ALLO‑316 in renal cell carcinoma, and the RESOLUTION Phase 1 autoimmune basket study of ALLO‑329 using its Dagger® platform to potentially reduce or eliminate standard lymphodepletion.
Allogene Therapeutics, Inc. reported second quarter 2026 results and key clinical updates. The pivotal Phase 2 ALPHA3 trial in first-line large B-cell lymphoma showed interim minimal residual disease (MRD) data at the protocol-defined cutoff: 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity versus 16.7% (2/12) in the observation arm, a 41.6% absolute difference. Following review of this futility analysis, the FDA granted RMAT and Fast Track designations for cema-cel as first-line consolidation therapy in high-risk LBCL.
The company has already activated more than 80 ALPHA3 sites and now expects about 100 sites by year-end 2026, with enrollment of approximately 220 MRD+ patients projected to complete by year-end 2027 and an event-free survival update anticipated in mid-2027. In autoimmune disease, the Phase 1 RESOLUTION trial of ALLO-329 continues brisk enrollment, with a clinical and translational update expected in Q4 2026.
For Q2 2026, Allogene reported $4.64 million in collaboration revenue, $30.7 million in research and development expense and $20.8 million in general and administrative expense. Net loss was $42.7 million, or $0.13 per share, compared with $50.9 million a year earlier. Cash, cash equivalents and investments totaled $423.6 million as of June 30, 2026, and the company projects its cash runway into 2029. 2026 operating expense guidance is approximately $165 million (GAAP operating expenses about $225 million, including roughly $35 million of non-cash stock-based compensation).
Allogene Therapeutics, Inc. reports that investor and director Arie Belldegrun and affiliated entities have amended their passive ownership report. As of May 11, 2026, Dr. Belldegrun beneficially owns 13,610,578 shares of Allogene common stock, representing 3.9% of the 345,154,561 shares outstanding. His total includes 4,010,524 shares issuable within 60 days upon exercise of stock options and shares held through Bellco Legacy entities and Vida Ventures funds. The filing confirms that each reporting person now owns 5% or less of the outstanding common stock, with joint filing across the listed entities.
State Street Corporation reported beneficial ownership of 19,025,826 shares of Allogene Therapeutics, Inc. common stock on a Schedule 13G. This represents 5.5% of the class of Allogene’s common shares.
State Street reports no sole voting or dispositive power, with shared voting power over 18,772,433 shares and shared dispositive power over 19,025,826 shares. Subsidiaries involved include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.
Allogene Therapeutics President and CEO Zachary Roberts reported equity awards rather than open-market trades. He received a grant of 476,190 stock options to buy common stock at an exercise price of $2.11 per share, expiring on July 1, 2036. Twenty-five percent of these options vest on July 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Roberts was also granted 134,530 Restricted Stock Units, each representing one share of common stock. These RSUs vest in four equal annual installments over the four-year period starting July 20, 2026, subject to his continued service. The filing shows compensation-related acquisitions, with no reported stock purchases or sales in the market.
Allogene Therapeutics director Joshua A. Kazam reported equity compensation activity. On June 18, 2026, he exercised 47,700 Restricted Stock Units (RSUs), which converted into the same number of common shares, bringing his direct common stock holdings to 398,463 shares after the transactions.
On the same date he received a new award of 95,400 RSUs under the company’s 2018 plan. Each RSU represents a contingent right to receive one share of Allogene common stock, or cash at the company’s discretion, and will vest in two equal semi-annual installments over one year, subject to continued service.
MESSEMER DEBORAH M. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Deborah M. Messemer received a grant of 95,400 restricted stock units (RSUs). The award carries no purchase price and gives her the contingent right to receive 95,400 shares of Allogene common stock if the units vest.
According to the terms, the RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, subject to her continued service through each vesting date. Following this grant, she holds 95,400 RSUs directly.
Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock. The options have an exercise price of $2.00 per share and vest in 12 equal monthly installments. Following this award, he holds options for 144,400 shares, expiring on June 18, 2036.
Allogene Therapeutics director Vicki L. Sato received a grant of 95,400 Restricted Stock Units. These RSUs give her the right to receive an equal number of Allogene common shares at future vesting dates, without paying an exercise price.
The award will vest in two equal semi-annual installments over one year from the grant date, as long as she continues to provide service through each vesting date. This filing does not report any open-market purchases or sales, only a compensation-related equity grant.
WITTE OWEN N. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Owen N. Witte received a grant of 95,400 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date.
Witte has elected to defer receipt of the underlying common shares until the earlier of 30 days after his separation from continuous service with the company or a change in control of Allogene, in line with the company’s Non-Employee Director Compensation Policy.